Castleview Partners’s Adient ADNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-85
Closed -$3.09K 901
2023
Q4
$3.09K Hold
85
﹤0.01% 649
2023
Q3
$3.12K Hold
85
﹤0.01% 522
2023
Q2
$3.26K Hold
85
﹤0.01% 548
2023
Q1
$3.48K Hold
85
﹤0.01% 529
2022
Q4
$2.95K Hold
85
﹤0.01% 493
2022
Q3
$2K Hold
85
﹤0.01% 519
2022
Q2
$2.52K Buy
+85
New +$2.86K ﹤0.01% 617
2022
Q1
Sell
-4,069
Closed -$85 707
2021
Q4
$85 Buy
+4,069
New +$183K ﹤0.01% 832
2021
Q2
$4K Buy
+85
New +$3.98K ﹤0.01% 803

Other funds holding ADNT

Castleview Partners's ADNT Position: Q1 2024 in Review

Castleview Partners sold out of Adient (ADNT) in Q1 2024, closing a stake of 85 shares — an estimated $3.09K sold.

Castleview Partners first reported a position in ADNT in Q2 2021 and held it in 9 quarters. The position peaked at $4K in Q2 2021. 311 funds tracked by Wall St. Rank hold ADNT as of Q1 2024.

  • Castleview Partners reported no remaining Adient position as of Q1 2024 after selling out during the quarter.
  • Castleview Partners sold 85 Adient shares in Q1 2024, an estimated $3.09K.
  • Castleview Partners first reported a position in Adient in Q2 2021 and held it in 9 quarters.
  • Castleview Partners's Adient position peaked at $4K in Q2 2021.
  • 311 funds tracked by Wall St. Rank held Adient as of Q1 2024.

Based on Castleview Partners's 13F filing for Q1 2024, filed 10 May 2024.